Paul Reider - 13 Dec 2023 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role
Chief Commercial Officer
Signature
/s/ Bryan McMichael, as Attorney-in-Fact for Paul Reider
Issuer symbol
CHRS
Transactions as of
13 Dec 2023
Net transactions value
-$4,856
Form type
4
Filing time
15 Dec 2023, 16:47:23 UTC
Previous filing
15 Jun 2023
Next filing
04 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CHRS Common Stock Tax liability $4,856 -2,049 -2.3% $2.37 88,406 13 Dec 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3.
F2 Includes 3,402 shares acquired on May 15, 2023 pursuant to the Coherus BioSciences, Inc. Employee Stock Purchase Plan.